Shows
BioBusiness.TV, the podcast! ver2ASBMR Review - Part 1: AMGN Makes NewsYou are Watching:
Post ASBMR Review: Amgen's Denosumab Lowers Fracture Risk, Makes the News at the American Society for Bone and Mineral Research (ASBMR) meeting.
Mike is back from a very exciting American Society for Bone and Mineral Research (ASBMR) meeting in Montreal. Amgen made the news with the results of its phase 3 trial for Denosumab. Mike explains Denosumab sets a new standard for a highly efficacious, safe, and convenient treatment for a disease that has a very high unmet need, despite its prevalence. Mike and Jean-Loup comparison Denosumab to Novartis' Reclast and other Bisphosphonates - looking at safety, tolerability...2008-09-1901 minBioBusiness.TV, the podcast! ver2ASBMR Review - Part 2: AMGN StrategyYou are Watching:
Post ASBMR Review: Denosumab to Seize Low Hanging Fruit in Osteoporosis Market, with the Potential to Become 1st Line Treatment. Amgen's Currently Inexpensive Shares to Gain 20 points.
After reviewing the Denosumab data released at the ASBMR meeting, it looks like Amgen's osteoporosis drug will be a 2nd line treatment. With 50% of osteoporosis patients going off their bisphosphonates in their fisrt year, Mike King thinks there is a low hanging fruit there. Mike also thinks the drug's profile could allow it to quickly become a first line treatment. Jean-Loup and Mike look at the market, Amgen's pricing for...2008-09-1910 minBioBusiness.TV, the podcast! ver2ASBMR Review - Part 3: Pfizer, MerckYou are Watching:
Post ASBMR Review: A quick look Pfizer's Fablyn, and Merck Odanacatib.
Mike and Jean-Loup take a quick look at some of the other data released at the American Society for Bone and Mineral Research Meeting in Montreal. They review Pfizer's PEARL study for the drug Fablyn, and Merck's phase 2 Odanacatib.
This interview was conducted at the NASDAQ Marketsite, on September 19th, 2008, in New York City.
Featuring:
* Michael King, Director of Research, Rodman & Renshaw
* Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV
DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS...2008-09-1900 minBioBusiness.TV, the podcast! ver2PARD CEO Interview - Part 1You are Watching:
Poniard’s Platinum Compound for Oncology, A Winning Design for its Clinical Trial
How does one go about creating value with a platinum compound? In this interview Mike King asks Jerry McMahon of his rather broad use of Picoplatin in Oncology. They review the SPEAR clinical trial in Small Cell Lung Cancer, its design, endpoints, timeline, competitive landscape, and favorability with the FDA.
This interview was conducted at the NASDAQ Marketsite, on September 8th, 2008, in New York City.
Featuring:
* Jerry McMahon, Chairman and Chief Executive Officer, Poniard Pharmaceuticals
* Michael King, Director of Research, Rodman & Renshaw
DISCLAIMER:
BIOBUSINESS.TV...2008-09-0808 minBioBusiness.TV, the podcast! ver2PARD CEO Interview - Part 2You are Watching:
Picoplatin in Colorectal, Prostate, Ovarian Cancer and NSCLC, and Poniard’s $100M Cash Position
Poniard has begun clinical trials of it’s Picoplatin in combination with other standard of care therapies. Jerry McMahon and Mike King discuss these indications and the different strategies for each one. Jerry tells us about the data presented in these trials at the latest ASCO meetings. Finally they review Poniard’s very attractive cash position, and its plans for partnering in the years to come.
This interview was conducted at the NASDAQ Marketsite, on September 8th, 2008, in New York City.
Featuring:
* Jerry McMaho...2008-09-0801 minBioBusiness.TV, the podcast! ver2DNA + Roche Deal Review with Mike KingYou are Watching:
Roche and Genentech, Deal Review, with Mike King.
Mike King and Daniel Teper discuss the Genentech / Roche deal. Genentech’s Board of Directors say $89 per share is inadequate, Roche’s management feels it is more than generous. Genentech shareholders like this stock, and are reluctant to sell for less than $120-135. Why does Roche want the remaining 56% of Genentech? Will Roche be able to retain the innovation that made Genentech so successful? What are the odds of this deal closing?
This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City.
Featuring:
* Michael King...2008-08-1301 minBioBusiness.TV, the podcast! ver2IMCL + BMS Deal Review with Mike KingYou are Watching:
BMS and ImClone Deal Review, with Mike King.
Why is BMS after ImClone, and what will happen next? Carl Icahn’s says the $60 bid is too low. Mike King believes Icahn is waiting for the Genentech Roche transaction to play out, in order to see the valuation metrics that will be used in that transaction. Mike and Daniel continue to discuss the integration of ImClone within BMS, the international rights to Erbitux, and the odds of this transaction closing.
This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City.
Featuring:
* Michael King, Di...2008-08-1301 minBioBusiness.TV, the podcast! ver2Mike King on Summer AcquisitionsYou are Watching:
Impact of Summer Acquisitions on the Biotech Industry, with Mike King.
With close to $60Bn worth of biotech stock that could be removed from the market, where will this money go? Where will investors be putting their money? Mike thinks it will flow back into the group as there are still some attractive investment opportunities. Mike and Daniel further discuss the disappearance of the large cap leaders, who would take over the leadership position, and the potential for future acquisitions.
This interview was conducted at the NASDAQ Marketsite, on August 13th, 2008, in New York City.
Featuring:
* Michael...2008-08-1304 minBioBusiness.TV, the podcast! ver2ASCO 2008 Review - Part 1: The Take HomeYou are Watching:
ASCO 2008, the take home message with Mike King.
What should all investors know about this year’s ASCO? What is the take home message? Mike King tells us it hasn't been a momentous ASCO. ImClone was most affected. Mike and Daniel look at the behavior of stocks before and after the meeting, and reflect on the impact of abstract releases, preceding this year's ASCO.
This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in New York City, on the occasion of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Featuring:
* Michael Ki...2008-06-0502 minBioBusiness.TV, the podcast! ver2ASCO 2008 Review - Part 2: IMCLYou are Watching:
ASCO 2008, Focus on Imclone with Mike King.
What happened to ImClone's stock after ASCO this year? Mike King tells us about the expectations, the fluctuations, and what he believes was a misinterpretation of the FLEX trial results. Mike foresees a strong market for Erbitux, in the years to come, with positive impact on ImClone's earnings. Also discussed in this interview is the KRAS mutation, its impact on Erbitux's market penetration and on Imclone's earning, as well as the interest doctors and payers have in it.
This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in...2008-06-0501 minBioBusiness.TV, the podcast! ver2ASCO 2008 Review - Part 3: DNAYou are Watching:
ASCO 2008, Focus on Genentech with Mike King.
In a Post-ASCO review Mike King reviews Genentech. Can the 2 months Avastin and 5 weeks Erbitux data be compared? Apples and oranges, according to Mike! The subgroups tell a completely different story. Mike is optimistic with regard to Genentech's performance. It has seen a strong growth in Non Small Cell Lung Cancer (NSCLC), and should see growth in Metastatic Breast Cancer too. Mike sets a $92 price target on Genentech's stock; outperform.
Update: Genentech’s stock (DNA) reached $93.88 on July 21st, from $73 on the day of this interview. Hats off!
This interview wa...2008-06-0501 minBioBusiness.TV, the podcast! ver2ASCO 2008 Review - Part 4: CELGYou are Watching:
ASCO 2008, Focus on Celgene with Mike King.
Celgene in a Post-ASCO review, reveals positive data. Mike King discusses the multiple myeloma survival data and its impact on Revlimid. Mike compares Celgene's Revlimid and (Takeda's) Millenium's Velcade. Is complete response the best predictor of outcome? How do the other parameters of the studies come into play? Mike gives us a projection for the sales of Revlimid and a price target for Celgene at $72. Last he touches upon the question of Celgene's acquisition. Would it make any sense?
Update: Celgene’s stock (CELG) reached $72.63 on July 21st, from $63.35 on th...2008-06-0501 minBioBusiness.TV, the podcast! ver2ASCO 2008 Review - Part 5: Small CapsYou are Watching:
ASCO 2008, Small Cap Focus with Mike King.
ASCO can be full of surprises for some of the smaller caps. Mike King from Rodman & Renshaw reviews a few names that include Poiniard, MedRx, and Celldex/Avant.
This interview was conducted at the NASDAQ Marketsite, on June 5th, 2008, in New York City, on the occasion of the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Featuring:
* Michael King, Director of Research, Rodman & Renshaw
* Daniel Teper, Managing Director of Bionest Partners, and Founder & Chairman of BioBusiness.TV
DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM...2008-06-0501 min